Menu

Reports

01 AA007239

US biosimilars approvals expected to increase despite challenges

Home/Reports | Posted 27/03/2015

Biosimilar approvals in the US are expected to increase during the next five years, despite safety and regulatory challenges, according to a study from the Boston-based Tufts Center for the Study of Drug Development (CSDD).

Biological large Hanyang Univ V15c13

Biosimilars will only be developed for blockbuster biologicals

Home/Reports | Posted 13/03/2015

A new report, published on 24 February 2015, by pharmacy benefits management (PBM) company Prime Therapeutics, suggests that only blockbuster biologicals in the US will be subject to biosimilar competition in the future.

Brazil looks to follow-on biological products to contain costs

Home/Reports | Posted 27/02/2015

Brazil’s Government is looking at measures to control the rising cost of healthcare. With increasing demand for life-saving biologicals the government is considering follow-on biological products as a more cost-effective option [1].

Generics Blue Cap V13C15

Generics gaining ground in French pharmaceutical market

Home/Reports | Posted 20/02/2015

The French pharmaceutical market is forecast to grow by a miniscule amount in the coming years due to the growing influence of generics in the country.

Pay for Delay DrugsMoneyGeneric V13F21

US pay-for-delay deals decrease in 2013

Home/Reports | Posted 13/02/2015

During 2013, companies filed a total of 145 final patent dispute settlements, of which 29 were potentially anticompetitive or ‘pay-for-delay’ agreements between brand-name and generics companies, according to a new report released on 22 December 2014 by the US Federal Trade Commission (FTC).

Health Canada V13I20

Generics still cost more in Canada, but prices decreasing

Home/Reports | Posted 06/02/2015

A report issued in December 2014 by Canada’s Patented Medicine Prices Review Board (PMPRB) finds that the prices of generics in Canada have decreased significantly in recent years. However, Canadians are still paying more for their generics than patients in many other countries.

Patent 1 V13E17

EU problematic patent settlements stabilize

Home/Reports | Posted 09/01/2015

The number of patent settlements between originator and generics companies concluded during 2013 has reduced compared to 2012. While the number of problematic or so-called ‘pay-for-delay’ deals have stabilized compared to 2012.

Generic Brand Name V13C01

UK uses less brand-name medicines per person

Home/Reports | Posted 12/12/2014

The UK uses fewer brand-name medicines per person than many other countries, but this means that the country tends to use older medicines rather than the latest ones, according to a new report.

Patent 1 V13E17

Generics makers challenging more patents

Home/Reports | Posted 05/12/2014

In recent years generics makers are becoming bolder and challenging more patents on originator drugs. In fact, litigation regarding patents on pharmaceuticals is on the rise, particularly when it comes to newer drugs.

Health Budget 1 V13D12

Generics and biosimilars contribute to European drug savings

Home/Reports | Posted 17/10/2014

As governments around the world try to rein in healthcare expenses, generics and biosimilars can play a major role in reducing this budgetary burden [1, 2].